1. Az Ospedaliero Universitaria di Ferrara
This house believes that neoadjuvant systemic therapy should be the standard of care for HER2+/triple negative operable breast cancer > 2cm
Discussion
Antonio Frassoldati
Oncologia Clinica
Az Ospedaliero Universitaria di Ferrara

2. When a therapy becomes standard?
Class I evidence of improvement in OS in respect with the previous standard
If not for OS, evidence of improvement in DFS
If not for OS and DFS, evidence of improvements in QoL, side effect profile or costs.

3. Neoadjuvant vs adjuvant
Mauri, JNCI 2005

4. What is the benchmark? Results of adjuvant therapies
Might NAST strategy improve this figure through a personalized approach?
HER2+: B31/N9831, JCO 2011; TN : E1199, SABCS 2014, BCCA group

5. Challenge of demonstrating improved EFS with neoadjuvant therapy
Presented By Angela DeMichele at 2015 ASCO Annual Meeting

6. Increased pCR rate with multiple antiHER2 agents
Multiple block with chemotherapy plus T+L, or T+P, versus single block

7. Increased pCR rate with Carboplatin or Bevacizumab in TNBC
Chen, PlosOne 2014

8. Prognostic Predictive
The possibility to increase pCR does justify the neoadjuvant use?
Prognostic Predictive
Presented By Angela DeMichele at 2015 ASCO Annual Meeting

9. Trial-level correlation between treatment effect on pCR and outcome
Little association between increase in frequency of pathological complete response and treatment’s effect on EFS or OS
Cortazar, Lancet 2014

10. Why NAST results do not translate in long-term results?
In most trials, heterogeneous tumour subtypes were enrolled: possible effect due to different response in different subtypes.
A targeted therapy was used in only three trials (GeparQuattro, NOAH and TECHNO) (and adjuvant trastuzumab used only in NOAH): the degree of difference in pCR is important for long term outcome.
Postoperative therapy could have partly contributed to the treatment effect.
Factors unrelated to primary tumour response could have had a role.

11. NAST in more homogeneous tumors Patient-level Meta-Analysis azard Ratios for pCR vs No pCR in HER2+ BC
Broglio, Jama Oncol 2016

12. Trial-level Treatment Benefit for pCR vs Corresponding EFS-HR Between Treatment Arms for Randomized Trials in HER2 BC
Modest correlation with pCR odds ratio and EFS HR, but not with OS HR
Broglio, Jama Oncol 2016

13. Why NAST should be the standard?
Increase in the rate of breast conservation
Improvement in axillary surgery (avoiding axillary clearence in cN1 pts)
Increase in the disease outcome (DFS, DDFS, OS)?
Increase the kwnoledge of the disease behavior (prognostic; useful for adjuvant phase)
Increase in the possibility of tailoring therapies (to increase the pCR or the long term outcomes)

14. Response and survival to NAST of intrinsic subtypes
n-pCR
pCR
Prat, BMCmed 2015

15. How precise we are in selection of the optimal candidate to NAST?
Caray , ASCO 2013

16. PIK3CA mutation is associated with lower activity of anti-HER2 agents
Loibl, Ann Oncol 2016

17. TN subtypes are associated with different probability of pCR with NAST
Lehmann, PlosOne 2016

18. Odds ratio of pCR vs n-pCR by type of TN subtype classifier
Lehmann, PlosOne 2016

19. pCR rate according to disease subtypes and TILs
Carbognin, The Oncologist 2016

20. NAST: already standard or still a model for reasearch?
Are the endpoints of therapy the same if therapy is given before or after surgery?
Some of them can be influenced by the timing of therapy
The tumor biology may not be the same for primary or micrometastatic tumor cells

21. Tumor dormancy of micrometastatic disease
Evans, WJCO 2015

22. Clinical and Prognostic information How we practically use them (EBM guided)?
Change the type of surgery
Reassure the patient if pCR
Change the adjuvant strategy
Change the duration of treatments
Change the type of radiation
Change the type of controls during the follow-up

23. If NAST is standard, which standard after NAST?
For HER2+ BC, trastuzumab up to one year can be considered standard (even if pCR?)
What to do if HER2 status changes? (stop or go trastuzumab?)
No established guideline for Chemo in tumors with residual disease at surgery (other chemo? which chemo?)
No established radiotherapy strategy for cN+ becoming ypN0, nor for large tumor obtaining good PR but undergoing to mastectomy. (RT on axilla? RT after mastectomy?
Maybe more questions than answers generated by NAST

24. Which lessons from the NAST story?
Tumor selection is the first point – we are still imprecise
Patient involvement in the decision is the second point – an honest discussion about the endpoints, the potential true benefits and the limits of NAST must be done
NAST remains the best model to study the activity of new drugs and to evaluate the “in vivo” effects of them, even if it is not automatically the same in other tumor settings.

25. NAST in HER2+ & TNBC
NAST is NOT the standard, but is one of the possible standards (to be carefully selected for the right situation)